Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with Tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. Objective: Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis....
Saved in:
Main Authors: | Connie Celum, Ting Hong, Anne Cent, Deborah Donnell, Rhoda Morrow, Jared M. Baeten, Cynthia Firnhaber, Beatriz Grinsztejn, Mina C. Hosseinipour, Umesh Lalloo, Mulinda Nyirenda, Cynthia Riviere, Jorge Sanchez, Breno Santos, Khuanchai Supparatpinyo, James Hakim, N. Kumarasamy, Thomas B. Campbell |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019691645&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/57733 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with Tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study
by: Connie Celum, et al.
Published: (2018) -
Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with Tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study
by: Celum C., et al.
Published: (2017) -
Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: A focused safety analysis of ACTG PEARLS (A5175)
by: Touzard Romo,F., et al.
Published: (2015) -
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated with Virologic Failure: Results from the Multinational PEARLS (ACTG A5175) Clinical Trial
by: Kantor R., et al.
Published: (2015) -
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
by: Beatriz Grinsztejn, et al.
Published: (2019)